Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial
touchONCOLOGY joins Dr Omid Hamid (Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Los Angeles, CA, USA) at ASCO 2021 to discuss nemvaleukin alfa and the ARTISTRY-2 trial.
The abstract ‘Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2’ (NCT03861793) (abstract number 2552) was presented at the 2021 ASCO Annual Meeting.
Questions
1. Could you tell us a little about nemvaleukin alfa and its mechanism of action? (0:15-01:32)
2. What are the aims of the ARTISTRY clinical trial program, and what have we learned to date? (01:32-02:49)
3. Which tumour types were included in ARTISTRY-2? (02:49-04:09)
4. What were the efficacy and safety findings of ARTISTRY-2? (04:09-05:15)
5. What will be the next steps in the ARTISTRY clinical trial program? (05:15-07:26)
Disclosures: Consulting/Advisory Boards: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, Seattle, Genetics, Tempus, Zelluna. Speaker Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron. Contracted Research (For Institution): Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
